SEC Comment Letter for GSK (GSK) — Jul 14, 2014
GSK plc
Date: July 14, 2014 · CIK: 0001131399 · Accession: 0000000000-14-035252
AI Filing Summary & Sentiment
Show Raw Text
July 11 , 201 4 Via E -mail Mr. Simon Dingemans Chief Financial Officer GlaxoSmithKline plc 980 Great West Road Brentford, Middlesex TW8 9GS England Re: GlaxoSmithKline plc Form 2 0-F for Fis cal Year Ended December 31, 2013 Filed February 28, 2014 File No. 001 -15170 Dear Mr. Dingemans : We have completed our review of your filing. We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filing and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable rules require. Sincerely, /s/ Joel Parker Joel Parker Accounting Branch Chief